LegalView Reports Development of a Breakthrough Study Explaining How Asbestos Causes Mesothelioma Cancer

Share Article

LegalView recently reported of a study by scientists at Ohio State University who are attempting to determine the molecular details of how asbestos fibers bind to human cancer cells. The scientists hope that with the study, they will eventually be able to produce more adequate mesothelioma treatments.

to observe how a single asbestos fiber binds with a specific receptor protein on cell surfaces, the most comprehensive legal resource available on the Internet, recently informed its mesothelioma information blog readers of the development of a breakthrough study by Ohio State University researchers as to how asbestos fibers bind to human cells to cause the deadly condition known as mesothelioma. The scientists will be using a method known as atomic force microscopy "to observe how a single asbestos fiber binds with a specific receptor protein on cell surfaces," according to a Dec. 22 Science Daily news article. Although the study is years away from being complete, scientists hope that one day they may be able to offer a better understanding of the development of the condition, which will result in a more comprehensive knowledge of the disease and more adequate treatments.

Mesothelioma cancer is a condition that occurs in individuals who have inhaled asbestos fibers and/or dust. The condition causes cancerous cells to form on the internal lining of the lungs and, after 10 to 30 years, signs and symptoms of the condition begin to develop. Because mesothelioma cancer remains largely in a dormant state for the duration of its life in a victim, by the time its symptoms develop it is often untreatable.

Individuals who suffer from the deadly cancer should consider speaking with an experienced mesothelioma lawyer as to the details surrounding a potential mesothelioma lawsuit. Such a meeting could benefit anyone suffering from mesothelioma symptoms by resulting in monetary compensation, which may assist a victim in receiving expensive and potentially life-saving treatments.

LegalView also offers an array of other legal topics available through its LegalView library. For example, the site has made available the latest information on brain injury treatments as well as information on controversial prescription drugs such as Chantix and Singulair, which have both been linked to suicidal thoughts and tendencies among patients, according to U.S. Food and Drug Administration reports.

LegalView recently updated its TBI information portal with a new therapy known as hyperbaric oxygen therapy (HBOT), which is often used among divers when bends occur. However, new research is finding that HBOT may offer success among brain injured victims by administering the therapy among U.S. soldiers as a brain injury treatment. To learn more of the treatment, visit the LegalView brain injury information portal at

Both Chantix and Singulair have been linked to an increase of behavioral and mood disorders as well as depression, increased suicidal tendencies, thoughts and actions; although both drugs treat very different conditions. Chantix is a smoking cessation drug that has been prescribed to nearly 4 million U.S. citizens whereas Singulair is used to treat allergies and asthma among Americans. If a victim suffers from either the Chantix risks or the Singulair side effects, they are encouraged to locate an experienced pharmaceutical attorney for assistance on developing a potential class action lawsuit.

About LegalView is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Katie Kelley

Alan Haburchak
Visit website